APOGEE THERAPEUTICS, INC. COMMON STOCK
NASDAQ: APGE (Apogee Therapeutics, Inc.)
Last update: 1 hour ago70.39
-0.53 (-0.75%)
| Previous Close | 70.92 |
| Open | 72.71 |
| Volume | 449,526 |
| Avg. Volume (3M) | 733,793 |
| Market Cap | 4,809,060,864 |
| Price / Book | 7.72 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Diluted EPS (TTM) | -3.61 |
| Total Debt/Equity (MRQ) | 1.75% |
| Current Ratio (MRQ) | 15.82 |
| Operating Cash Flow (TTM) | -188.02 M |
| Levered Free Cash Flow (TTM) | -120.81 M |
| Return on Assets (TTM) | -19.65% |
| Return on Equity (TTM) | -27.85% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Apogee Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -3.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.40 |
|
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 7.62% |
| % Held by Institutions | 137.71% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2025 | 8,493,321 |
| Fmr Llc | 30 Sep 2025 | 6,916,462 |
| Wellington Management Group Llp | 30 Sep 2025 | 4,723,701 |
| Rtw Investments, Lp | 30 Sep 2025 | 2,712,097 |
| Driehaus Capital Management Llc | 30 Sep 2025 | 2,158,502 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 2,048,647 |
| Paradigm Biocapital Advisors Lp | 30 Sep 2025 | 1,521,757 |
| Braidwell Lp | 30 Sep 2025 | 1,438,745 |
| Alliancebernstein L.P. | 30 Sep 2025 | 1,419,132 |
| Affinity Asset Advisors, Llc | 30 Sep 2025 | 1,173,426 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 115.00 (BTIG, 63.38%) | Buy |
| Median | 105.00 (49.17%) | |
| Low | 70.00 (RBC Capital, -0.55%) | Buy |
| Average | 97.20 (38.09%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 50.88 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 03 Nov 2025 | 109.00 (54.85%) | Buy | 54.35 |
| RBC Capital | 03 Nov 2025 | 70.00 (-0.55%) | Buy | 54.35 |
| 25 Sep 2025 | 60.00 (-14.76%) | Buy | 37.52 | |
| Mizuho | 21 Oct 2025 | 105.00 (49.17%) | Buy | 55.87 |
| BTIG | 09 Oct 2025 | 115.00 (63.38%) | Buy | 53.21 |
| B of A Securities | 28 Aug 2025 | 87.00 (23.60%) | Buy | 36.62 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HENDERSON JANE | - | 65.50 | -2,000 | -131,000 |
| Aggregate Net Quantity | -2,000 | |||
| Aggregate Net Value ($) | -131,000 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 65.50 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HENDERSON JANE | Officer | 14 Nov 2025 | Automatic sell (-) | 2,000 | 65.50 | 131,000 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |